CardioDynamics Reports Third Quarter 2008 Results, Seventh Consecutive Quarterly Revenue Growth and 15% Year to Date Revenu...(mbination of a 12% increase inthird quar...)

Date:10/9/2008

mbination of a 12% increase in third quarter ICG device sales along with a 10% increase in the average unit sales price of our ICG Monitors compared with the third quarter of 2007. This increase in average unit selling price is principally due to a proportionately greater number of higher priced BioZ Dx systems sold during the third quarter of 2008, as compared to the third quarter of 2007 and lower sales return reserve requirements.

Gross margin as a percentage of sales increased from 72% to 75% in the third quarter of 2008, largely due to a 10% average unit sales price improvement, lower inventory reserve requirements, reduced manufacturing overhead costs, and a reduction of sales returns reserve.

Operating expenses were reduced 8% (or $398,000) to $4.8 million, driven primarily by improved efficiencies, reduced personnel expenses, lower accounting fees and bad debt provisions, all part of an ongoing cost containment focus in support of the Company's plan to regain profitability.

The operating loss improved 78% to $254,000, compared to an operating loss of $1.2 million for the same period in 2007. The year-to-date operating loss was $1.6 million, a 61% improvement from $4.0 million in the same nine month period of 2007.

CEO Comments and Outlook

Michael K. Perry, Chief Executive Officer of CardioDynamics, stated, "We were very pleased with our performance in the third quarter, particularly the rate of improvement we are making in reducing the operating loss. Excluding non-cash expenses for depreciation, amortization and stock option compensation, we experienced positive income from operations for the first time in 15 quarters and one quarter ahead of plan. Achieving our seventh consecutive quarterly year-over-year revenue growth and 15% growth year-to-date is encouraging and a testament to the continued growth potential for ICG."

Perry continued, "Our goal remains to achieve positive operating cash flow in the fourth quarte
'/>"/>

SOURCE CardioDynamics Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. CardioDynamics BioZ(R) ICG Technology Integrates with General Electric Healthcares Centricity(R) Electronic Medical Record (EMR) System
2. CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Companys Common Stock and Trading in Post-split Shares Begins May 9, 2008
3. CardioDynamics Receives Nasdaq Letter of Non-Compliance With Minimum Bid Price Requirement
4. CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series
5. CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego
6. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
7. CardioDynamics Provides 2007 Shareholder Meeting Update
8. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. Corgenix Reports Fiscal 2008 Financial Results